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Abstract Danirixin (GSK1325756) is a small, high-
affinity, selective and reversible CXCR2 antagonist in
development for treatment of chronic obstructive pulmon-
ary disease. The objective of the study was to evaluate the
relative bioavailability, including the inter-subject vari-
ability, of a conventional immediate-release (IR) formula-
tion and two prototype bioenhanced formulations of
danirixin during gastric acid suppression in a healthy,
elderly population. A single-centre, crossover study in
healthy male and female volunteers aged 65–80 years was
conducted. Subjects were randomised to receive danirixin
50 mg IR in the fed and fasted states and danirixin 50 mg
Bioenhanced Formulation 1 and 2 in the fasted state. All
subjects also received omeprazole 20 mg each morning
beginning 4 days prior to the first treatment period and
continuing through danirixin dosing in the final treatment
period. Twenty subjects were randomised and completed
the study. Bioenhanced Formulation 2 in the fasted state
demonstrated the highest adjusted geometric means for
AUC(0–t), AUC(0–inf), AUC(0–24) and Cmax. Danirixin IR
demonstrated adjusted means that were higher in the fed
state compared with the fasted state. For all formulations
tested, there was substantial inter-subject variability (CVb
[100 % for all formulations). The overall incidences of
adverse events (AEs) were 10 % for danirixin IR (both in
the fed and fasted states) and 15–20 % for the bioenhanced
formulations. The majority of AEs were mild in intensity.
There were no serious AEs. Concomitant use of omepra-
zole resulted in large inter-subject variability in the expo-
sure to danirixin. Bioenhanced formulation strategies could
not overcome the effect of omeprazole on exposure and
variability between subjects.
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Danirixin  GSK1325756  Safety
1 Introduction
Danirixin (GSK1325756) is a small, non-peptide, high-
affinity (IC50 for CXCL8 binding 12.5 nM), selective and
reversible CXCR2 antagonist. Danirixin has demonstrated
potent antagonism of CXCR2 activity, both in vitro and
in vivo in preclinical studies (GSK, data on file). Its oral
potency and duration of action support its potential use as
an oral, anti-inflammatory agent in the treatment of disor-
ders associated with the accumulation of neutrophils.
B. E. Miller (&)  A. L. Lazaar
Clinical Discovery, Respiratory Therapy Area Unit,
GlaxoSmithKline R&D, 709 Swedeland Road,
King of Prussia, PA 19406, USA
e-mail: bruce.e.miller@gsk.com
K. Smart  C. L. Ambery
Clinical Pharmacology Modeling and Simulation,
GlaxoSmithKline R&D, Uxbridge, UK
S. Mistry
Clinical Statistics, GlaxoSmithKline R&D, Uxbridge, UK
J. C. Bloomer
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline
R&D, Uxbridge, UK
P. Connolly  D. Sanderson  T. Shreeves
Product Development, Platform Technology and Science,
GlaxoSmithKline R&D, Uxbridge, UK
R. Smith
Clinical Pharmacology Sciences and Study Operations,
GlaxoSmithKline R&D, Uxbridge, UK
Eur J Drug Metab Pharmacokinet (2014) 39:173–181
DOI 10.1007/s13318-014-0179-8
CXCR2, one of a family of CXC chemokine receptors,
is necessary for the chemokine-mediated recruitment of
neutrophils to sites of inflammation (Chapman et al. 2009).
The neutrophil is thought to be an important contributor,
via the release of tissue-destructive proteases and other
mediators, to excess mucus production, airway stenosis,
and destruction of the lung parenchyma which, in part, is
responsible for the decline in lung function associated with
chronic obstructive pulmonary disease or COPD (Stockley
2002; Quint and Wedzicha 2007). Levels of CXCL8
(interleukin-8) and other CXCR2 ligands (e.g. CXCL5 or
ENA-78) are elevated in bronchoalveolar lavage fluid and
the sputum of patients with COPD (Mukaida 2003). Sev-
eral molecules with CXCR2 antagonist activity have been
shown to reduce neutrophils migration to the lung in
experimental medicine studies and in diseased subjects
(Holz et al. 2010; Lazaar et al. 2011; Nair et al. 2012;
Rennard et al. 2013). Selective antagonism of the CXCR2
receptor provides a potential strategy for reducing the
underlying inflammation that contributes to the progression
of COPD and other neutrophil-mediated diseases (Chap-
man et al. 2009).
Danirixin has its highest solubility at pH \2. The for-
mulation strategy for the clinical development of danirixin
has been focussed on optimising dissolution in the stomach
to deliver a solution of the drug for absorption in the small
intestine. A raised intra-gastric pH could have a significant
impact on the dissolution and hence absorption of dani-
rixin. In fact, inter-subject variability in danirixin exposure
in elderly subjects, particularly in the fasted state and when
given on a background of proton pump inhibitor use has
been demonstrated, raising an important consideration for
designing clinical trials of danirixin in patient populations
(GSK 2013b).
Proton pump inhibitors and histamine H2-receptor
antagonists are widely used for the management of disor-
ders associated with excess gastric acid production (Blume
et al. 2006). Because these drugs are typically used for long-
term treatment, the potential for clinically significant drug
interactions exists. Gastroesophageal reflux disease is a co-
morbidity associated with COPD (Bor et al. 2010) and
gastric acid-suppressing medications are commonly used by
COPD patients. Though metabolic drug interactions (e.g.
with the cytochrome P450 system) are a concern with
several proton pump inhibitors, these agents may also alter
the exposure to drugs for which a low gastric pH is required
for optimal dissolution and subsequent absorption (Shi and
Klotz 2008; Blume et al. 2006; Budha et al. 2012). Addi-
tionally, reduced production of gastric acid in some elderly
subjects may also contribute to altered pharmacokinetics of
some drugs in this population (Russell et al. 1993).
The aims of the current study were to evaluate the
pharmacokinetics, with particular attention to inter-subject
variability of several formulations of danirixin, including
two bioenhanced formulations under conditions of gastric
acid suppression in healthy elderly subjects. The bioen-
hanced formulations were developed to determine if the
impact of a raised gastric pH on the pharmacokinetics of




The structure of danirixin is shown in Fig. 1.
The original immediate-release (IR) tablets contained
50 mg of danirixin free base and standard excipients
including mannitol, microcrystalline cellulose, HPMC,
croscarmellose sodium and magnesium stearate.
Two bioenhanced, immediate-release tri-layer tablet
formulations were manufactured by standard manufactur-
ing procedures. These formulations were developed with
the potential to enhance bioavailability compared to the
initial immediate-release formulation under conditions of
higher gastric pH. Tablets contained 25 mg of danirixin
free base. The two formulations were similar to the original
IR formulation with the exception of the addition of citric
acid in Bioenhanced Formulation 1 (BE1) and both citric
acid and poloxamer 407 in Bioenhanced Formulation 2
(BE2). In BE1, these modifications were made to enhance
the solubility of danirixin in higher pH environments by
reducing the localised pH around the disintegrating tablet,
and in BE2 poloxamer was also added to improve wetting
of the drug to aid dissolution.
2.2 In vitro solubility testing of danirixin
The determination of the pH solubility profile of danirixin
was performed by adding excess danirixin to the
Fig. 1 Danirixin free base
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appropriate pH Britton–Robinson buffer solutions in a vial.
The vial was then placed on a roller mixer for 4 h at
ambient temperature followed by filtration of a sample with
centrifugation using a microcentrifuge tube with a 0.45 lm
polyvinylidene difluoride membrane. The clear solution
was then assayed using a gradient reversed-phase HPLC
procedure to determine the danirixin content in solution.
The procedure used a Waters Sunfire C18 column with a
mobile phase of water and acetonitrile, containing 0.05 %
trifluoroacetic acid with detection by UV at 220 nm.
2.3 Subjects
Eligible subjects were male or non-childbearing female,
65–80 years of age, healthy as assessed by medical history,
physical examination, laboratory tests and cardiac moni-
toring, with a body weight C60 kg for men and C45 kg for
women, a body mass index 19–32 kg/m2, aspartate ami-
notransferase, alanine aminotransferase, alkaline phospha-
tase and bilirubin B1.5 9 upper limit of normal, and
resting blood pressure of B160/95 mmHg, irrespective of
anti-hypertensive medication status.
Key exclusion criteria included current or chronic his-
tory of liver disease or known hepatic or biliary abnor-
malities, a positive hepatitis B surface antigen or positive
hepatitis C antibody within 3 months of screening or a
positive test for human immunodeficiency virus antibody.
Patients were also excluded if they had a pre-study positive
drug/alcohol result, a history of regular alcohol consump-
tion or previous history of smoking within 6 months of
study, screening QT interval corrected using Bazett’s for-
mula[450 ms, a PR interval outside of 120–220 ms or an
electrocardiogram (ECG) not suitable for QT measure-
ments, a history of sensitivity to any of the study treatments
or its components, exposure to [4 new chemical entities
within 12 months prior to first dose, or use of prescription
or non-prescription drugs 7 months or five half-lives prior
to first dose.
2.4 Study design and treatment
This was an open-label, five-period crossover study (http://
www.clinicaltrials.gov identifier NCT01453478; GSK
study code CX3115550) conducted at a single centre
(Quotient Clinical Ltd., Nottingham, UK) between 12
October 2011 and 19 December 2011. The study was
approved by an independent ethics committee (Capenhurst
Independent Research Ethics Committee, Wirral, UK) and
conducted in accordance with the Declaration of Helsinki
2008 (WMA Declaration of Helsinki 2008) and ICH Good
Clinical Practice guidelines (ICH 1996). All subjects pro-
vided written informed consent prior to the start of the
study.
Following screening, subjects were randomised to
receive single doses of the following medications during
treatment periods 1 through 4: danirixin IR 50 mg in the
fed state (i.e. after a light breakfast), danirixin IR 50 mg in
the fasted state (i.e. after an overnight fast), danirixin BE1
50 mg (2 9 25 mg) in the fasted state or danirixin BE2
50 mg (2 9 25 mg) in the fasted state. In each treatment
period, all subjects received omeprazole 20 mg QD in the
morning for 5 days (Days -4 to Day 1) for gastric acid
suppression. On Day 1, the morning dose of omeprazole
was administered together with the applicable formulation
of danirixin 50 mg within a 5 min period. All treatment
periods were separated by a minimum washout period of
3 days. Subjects would be eligible to continue to Treatment
Period 5 if results of the interim analysis of the PK profile
and relative bioavailability of each formulation following
completion of Treatment Periods 1 through 4 met the pre-
specified criteria (i.e. inter-subject variability \50 %). If
these criteria were not fulfilled, the study would be ter-
minated following the completion of Treatment Period 4.
2.5 Outcomes and assessments
The primary PK end points included determination of area-
under-the-blood-concentration curve (AUC) data for dani-
rixin IR and two prototype bioenhanced formulations of
danirixin for the calculation of relative bioavailability
under fed and fasted conditions. Secondary PK end points
included characterisation of Cmax (maximum observed
concentration), Tmax (time of occurrence of Cmax) and
apparent terminal elimination half-life (t1/2). Safety and
tolerability were assessed by adverse events (AEs), vital
signs, ECGs, changes in clinical laboratory parameters
including clinical chemistry, haematology and urinalysis,
and changes in clinical signs and symptoms from physical
examination. Safety and tolerability data were summarised
by treatment group.
2.6 Measurements
PK samples (whole blood) were collected at pre-dose and
on Day 1 (0.5, 1, 2, 3, 4, 6, 8, and 12 h post-dose), Day 2
(24 and 36 h post-dose) and Day 3 (48 h post-dose). Whole
blood concentrations of danirixin free base were deter-
mined using a validated analytical method based on
extraction from a dried blood spot (Spooner et al. 2009),
with a 3 mm disc being punched from a 0.015 mL sample
on Whatman FTATM card. Danirixin was extracted using
methanol (0.1 mL) containing isotopically labelled [2H7]-
danirixin (racemic version of danirixin) at a concentration
of 50 ng/mL as an internal standard. The extraction tubes
were shaken for 1 h at ambient temperature, prior to the
supernatant being transferred to clean tubes. The
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supernatant was injected (5 lL) onto a high-performance
liquid chromatography system utilising a Thermo Scientific
Hypersil Gold C18 (5 lm packing 50 9 4.6 mm) column
(supplied by Thermo Scientific, Hempstead, UK), eluted
using an isocratic composition: 55:45 (v/v) of aqueous
10 mM ammonium formate containing 0.1 % formic acid
(A) and acetonitrile (B). Danirixin free base has a retention
time of approximately 1 min and was detected using tan-
dem mass spectrometry on a Sciex 5000 (Applied Bio-
systems, Warrington, UK) using TurboIon Spray in
positive polarity mode. Mass transitions monitored were 84
and 89 from precursor ions of 442 and 449 for danirixin
and the internal standard. The assay had a linear dynamic
range of 5–1,000 ng/mL and quantification was performed
using peak area ratios with 1/x2 weighted linear regression.
Assay quality control samples were 15 ng/mL, 200 ng/mL
and 800 ng/mL. The average within-run precision (%CV)
was 7.1, 3.2 and 3.3, respectively, for the low (15 ng/mL),
mid (200 ng/mL) and high (800 ng/mL) quality controls.
Interim and final PK analyses were carried out using
standard non-compartmental analysis and WinNonlin Pro-
fessional v5.2. All calculations of non-compartmental
parameters were based on nominal sampling times (relative
to dosing) for interim analyses and actual sampling times
for final analyses.
2.7 Statistical analysis
This sample size was chosen to provide acceptable preci-
sion to assess the study objectives and assuming similar
variability to previous studies (GSK 2013a, b). The All
Subjects population was defined as all subjects who
received at least one dose of danirixin. The PK population
was defined as all subjects in the All Subjects population
for whom a PK sample was obtained and analysed.
Analysis was performed following completion of
Treatment Period 4 and used the PK data collected during
Treatment Periods 1 through 4. The analysis compared
danirixin IR in the fed and fasted states, both bioenhanced
formulations in the fasted state with danirixin IR in the fed
and fasted states, and BE1 in the fasted state with BE2 in
the fasted state. The PK parameters AUC(0–t), AUC(0–inf),
AUC(0–24) and Cmax of danirixin underwent a natural log
transformation (loge). A mixed effects model was used to
analyse PK data and included an appropriate covariance
structure to provide different estimates of variance for each
treatment group; period, treatment and gender were used as
fixed effects and subject as a random effect. Point estimates
and 90 % confidence intervals (CIs) for each of the treat-
ment comparisons were constructed using the error vari-
ance obtained from the statistical analysis and were back
transformed to obtain estimates of the ratios of the adjusted
geometric means. The variability was assessed by
obtaining the within-subject variability (CVw) and CVb
from the statistical analysis. Distributional assumptions
underlying the statistical analyses were assessed by visual
inspection of studentised residual plots, and normality was
examined by normal probability plots (data not shown).
3 Results
3.1 In vitro solubility profile of danirixin free base
The pH solubility profile of danirixin free base is shown in
Table 1. At pH values above 2, the solubility of danirixin
free base was markedly reduced compared to the solubility
at a pH of 2.
3.2 Study population
Twenty healthy, white, elderly subjects were randomised
and all completed Treatment Periods 1 to 4 (Table 2). The
population was equally split between male and female
subjects; the mean age was 68.1 years (range 65–77 years).
3.3 Pharmacokinetic analysis
All subjects completed the four treatment periods and were
included in the pharmacokinetic analysis. The criteria to
progress to Treatment Period 5 were not fulfilled and the
study was terminated after Treatment Period 4. Pharma-
cokinetic parameters derived from whole blood concen-
trations of danirixin and subjected to statistical analysis are
shown in Table 3. Individual subject plots of whole blood
concentrations of danirixin over 48 h are shown in Fig. 2.
The adjusted geometric means for AUC(0–t), AUC(0-inf),
AUC(0–24) and Cmax were significantly higher for BE2 in
the fasted state compared with danirixin IR and BE1 in the
fasted state. In addition, adjusted geometric means for
AUC(0–24) and Cmax were significantly higher for BE2 in
the fasted state compared to danirixin IR in the fed state.
The adjusted geometric means for AUC(0–t), AUC(0–inf),
AUC(0–24) and Cmax were similar for BE1 in the fasted state
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and danirixin IR in the fed state. All adjusted geometric
mean parameters for BE1 in the fasted state were signifi-
cantly higher than danirixin IR in the fasted state, and
parameters for danirixin IR in the fed state were signifi-
cantly higher than danirixin IR in the fasted state. Com-
parisons of AUC and Cmax for the various formulations are
shown in Table 4.
For all formulations, there was substantial inter-subject
variability in exposure to danirixin; CVb values for all
AUC and Cmax parameters were greater than 100 %.
A statistically significant period effect was observed for
all parameters (AUC(0–t), p = 0.0010; AUC(0–inf), p =
0.0011; AUC(0–24), p = 0.0005; Cmax, p \ 0.0001), which
suggests that exposures in Treatment Period 1 were higher
than those observed for Treatment Periods 2 through 4.
For the IR formulation, the median Tmax was 3.5 h (2.0 -
4.0 h) in the fed state and 2 h (1.0 - 3.0 h) in the fasted
state. The apparent terminal half-life (t1/2) of danirixin was
similar across the formulations (approximately, 7–9 h).
3.4 Safety
Nine of the 20 subjects (45 %) reported AEs during the
study. There were no serious AEs and no withdrawals due
to AEs. There were no differences in the incidence of
reported AEs when danirixin IR was administered in the
fed or fasted state (both 10 %). The incidence of AEs after
administration of the BE1 and BE2 was 20 % and 15 %,
respectively. The only AE reported by more than one
subject was headache; 20 % of the subjects reported
headaches during the study. Two incidences of headache
(one after receiving danirixin IR and one after receiving
BE2) were considered to be drug related. All AEs were
reported to be mild in intensity, except for an AE of
headache in a subject administered BE2, reported to be of
moderate intensity; all AEs resolved. Haematology, clini-
cal chemistry and vital sign abnormalities of potential
clinical importance were isolated occurrences and were
only slightly outside the reference range. There were no
clinically significant ECG findings.
4 Discussion
In a previous study, when dosed concomitantly with the
proton pump inhibitor omeprazole, an immediate-release
Table 2 Subject disposition and demographics
Parameter Totala
Number of subjects planned, n 20
Number of subjects randomised, n 20 (100 %)
Number of subjects included in All Subjects
(safety) population, n
20 (100 %)
Number of subjects included in PK
population, n
20 (100 %)
Number of subjects withdrawn for
any reason, n
0
Age (years) 68.1 (65, 77)
Males, n 10 (50 %)
Body mass index (BMI) 26.5 (22.4, 32.0)
Height (cm) 165.7 (145.0, 180.0)
Weight (kg) 73.0 (54.6, 98.3)
Race (white/Caucasian/European heritage), n 20 (100 %)
Ethnicity (white, not Hispanic or Latino), n 20 (100 %)
a Values in () are percentage or ranges
Table 3 Summary of the statistical analysis of PK parameters for danirixin formulations—adjusted means and inter-subject variability
Parameter Treatment Adjusted geometric mean (90 % CI) CVb (90 % CI)
Cmax (ng/mL) IR fed 416.5 (278.1, 623.7) 144.38 (107.14, 232.43)
IR fasted 308.9 (214.8, 444.1) 120.41 (89.25, 195.71)
BE1 fasted 475.4 (335.8, 673.2) 111.80 (82.06, 186.87)
BE2 fasted 658.3 (438.6, 988.2) 144.83 (105.98, 241.93)
AUC(0–inf) (ng h/mL) IR fed 2,851 (2,006, 4,054) 115.34 (86.57, 181.64)
IR fasted 1,886 (1,321, 2,693) 115.87 (87.90, 177.74)
BE1 fasted 2,688 (1,951, 3,702) 99.72 (74.57, 158.80)
BE2 fasted 3,581 (2,525, 5,080) 112.40 (82.16, 190.09)
AUC(0–24) (ng/h/mL) IR fed 2,499 (1,750, 3,569) 117.86 (88.68, 184.39)
IR Fasted 1,699 (1,204, 2,397) 111.87 (84.60, 173.00)
BE1 fasted 2,448 (1,838, 3,375) 100.15 (74.86, 159.65)
BE2 Fasted 3,266 (2,306, 4,626) 111.94 (82.15, 187.25)
AUC(0–t) (ng h/mL) IR fed 2,688 (1,862, 3,879) 122.97 (91.75, 196.32)
IR fasted 1,785 (1,247, 2,554) 118.87 (89.44, 185.96)
BE1 fasted 2,558 (1,838, 3,560) 104.24 (77.59, 167.96)
BE2 fasted 3,470 (2,419, 4,979) 117.72 (85.36, 203.53)
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formulation of danirixin free base showed reduced expo-
sure and wide inter-subject variability compared to the
non-gastric acid suppression state. Though the effect of
omeprazole was expected based on the pH solubility profile
of danirixin free base, this drug interaction might limit the
use of danirixin in patient populations in which use of
proton pump inhibitors and histamine H2-receptor antag-
onists is common. The primary goal of the present study
Fig. 2 Individual subject time–blood concentration profiles
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was to determine if bioenhanced formulations of danirixin
free base could reduce the wide inter-subject variability in
exposure on a background of concomitant proton pump
inhibitor use (GSK 2013b). The study evaluated the rela-
tive bioavailability, including the inter-subject variability
of danirixin IR in the fed and fasted states and of two
prototype bioenhanced formulations of danirixin in the
fasted state during gastric acid suppression.
All formulations of danirixin, regardless of fed or fasted
state, exhibited substantial inter-subject variability (CVb
values [100 % for all formulations). This wide variability
in exposure is consistent with the results of a previous
study that investigated danirixin in the fed and fasted states
(GSK 2013b). However, the previous study did demon-
strate reduced variability in exposure when danirixin was
administered with food. The lack of improvement in vari-
ability with the bioenhanced formulations of danirixin in
the present study indicates that the tested formulations
cannot overcome the effects of gastric acid suppression on
danirixin pharmacokinetics. Regular, daily use of proton
pump inhibitors such as omeprazole will increase intra-
gastric pH levels to above 4.0 (Blum et al. 1997) and this
likely accounts for the reduction in exposure and the inter-
and intra-subject variability observed in the present study.
Systemic exposure to danirixin, in terms of AUC and
Cmax, was generally highest following Bioenhanced For-
mulation 2 compared with the other formulations in the
fasted state, but this was not associated with any reduction
in inter-subject variability. Systemic exposure following
the danirixin IR formulation was higher in the fed state
compared with the fasted state. The estimated terminal t1/2
values were similar for the different danirixin formulations
in this study (7–9 h) and were in line with previously
determined values, suggesting that the elimination of da-
nirixin was independent of formulation dose or fed/fasted
status, supporting the conclusion that dissolution and
absorption in the gastrointestinal track are major determi-
nants of systemic exposure following oral administration
(GSK 2013b).
In the present study danirixin exposures in Treatment
Period 1 were higher than exposures for the subsequent
treatment periods. It is unclear whether this unexpected
‘period’ effect is real as the exposure and variability of
danirixin are consistent with a prior study in which the
omeprazole interaction was evaluated (GSK 2013b). The
possibility of some variability over time in gastric pH due
to omeprazole is a potential explanation, though neither
gastric pH nor the PK of omeprazole was measured.
Table 4 Summary of the statistical analysis of PK parameters for danirixin formulations—treatment comparisons
Parameter Treatment comparison Ratio adjusted geometric mean (90 % CI)
Cmax (ng/mL) IR fed - IR fasted 1.35 (1.00, 1.81)
BE1 - IR fed 1.14 (0.87, 1.51)
BE2 - IR fed 1.58 (1.12, 2.24)
BE1 - IR fasted 1.54 (1.25, 1.90)
BE2 - IR fasted 2.13 (1.58, 2.87)
BE2 - BE1 1.38 (1.05,1.83)
AUC (0–inf) (ng h/mL) IR fed - IR fasted 1.51 (1.14,2.00)
BE1 - IR fed 0.94 (0.75,1.19)
BE2 - IR fed 1.26 (0.96,1.64)
BE1 - IR fasted 1.42 (1.11,1.82)
BE2 - IR fasted 1.90 (1.44,2.50)
BE2 - BE1 1.33 (1.07,1.66)
AUC (0–24) (ng h/mL) IR fed - IR fasted 1.47 (1.12,1.93)
BE1 - IR fed 0.98 (0.77,1.24)
BE2 - IR fed 1.31 (1.00,1.71)
BE1 - IR fasted 1.44 (1.15,1.80)
BE2 - IR fasted 1.92 (1.49,2.48)
BE2 - BE1 1.33 (1.07,1.66)
AUC (0–t) (ng h/mL) IR fed - IR fasted 1.51 (1.13,2.00)
BE1 - IR fed 0.95 (0.74,1.22)
BE2 - IR fed 1.29 (0.97,1.71)
BE1 - IR fasted 1.43 (1.13,1.82)
BE2 - IR fasted 1.94 (1.48,2.55)
BE2 - BE1 1.36 (1.08,1.71)
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Steady-state levels of omeprazole should have been
achieved prior to dosing on Day 1 of Treatment Period 1. It
does not appear that lack of compliance with the omepra-
zole dosing regimen during any of the treatment periods
was a factor.
Overall, all formulations of danirixin were well tolerated
in the healthy elderly population assessed in this study and
no major safety concerns were identified. The safety profile
was similar to that observed in prior studies (GSK 2013a,
b) and was not different between danirixin IR in the fed and
fasted states. The incidence of reported AEs with the bio-
enhanced formulations was similar, but slightly higher than
for danirixin IR. In the current study, there were no reports
of neutropaenia or sustained decreases in neutrophil count,
which is also consistent with previous single- and repeat-
dose danirixin studies (GSK 2013a, b).
This study has several strengths and potential limita-
tions. Overall, the study results are largely consistent with
those from a previous study of danirixin (GSK 2013a, b)
and the collective results from both studies will help to
guide selection of the most appropriate formulation/dosing
regimen for future investigations. The observed (and sta-
tistically significant) treatment period effect was unex-
pected and remains unexplained. However, this did not
interfere with the study objectives as the results with the
conventional immediate-release formulation were consis-
tent with previous studies.
In conclusion, although systemic exposures were higher
for Bioenhanced Formulation 2 of danirixin in the fasted
state than for any other formulation of danirixin during
either fasted or fed states, the bioenhanced formulations do
not confer any advantage over a conventional immediate-
release formulation with regard to inter-subject variability
on a background of concomitant proton pump inhibitor use.
Concomitant use of gastric acid suppressing medications
will need to be a consideration in the selection of appro-
priate subjects for further clinical development of danirixin.
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